- Drug Pipelines
- April 2024
- 50 Pages
Global
From €1432EUR$1,500USD£1,199GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- May 2024
- 128 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 139 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 136 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- June 2024
- 200 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Report
- June 2024
- 200 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Report
- June 2024
- 200 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Report
- January 2022
- 60 Pages
Global
From €3770EUR$3,950USD£3,159GBP
- Report
- January 2022
- 60 Pages
Global
From €3770EUR$3,950USD£3,159GBP
- Report
- January 2022
- 60 Pages
Global
From €3770EUR$3,950USD£3,159GBP
- Report
- January 2022
- 60 Pages
Global
From €3770EUR$3,950USD£3,159GBP
- Report
- May 2022
- 42 Pages
Global
From €1909EUR$2,000USD£1,599GBP

The Ichthyosis Drug market is a subset of the Dermatological Drugs market, which includes medications used to treat skin conditions. Ichthyosis is a group of rare, genetic skin disorders characterized by dry, scaly skin. Common treatments for Ichthyosis include topical creams, ointments, and oral medications. These drugs are used to reduce scaling, itching, and inflammation, as well as to improve skin hydration.
The Ichthyosis Drug market is highly specialized, with a limited number of products available. As such, the market is dominated by a few large pharmaceutical companies. These companies are focused on developing new treatments and improving existing ones.
Some of the major companies in the Ichthyosis Drug market include GlaxoSmithKline, Novartis, Pfizer, and Sanofi. These companies are actively researching and developing new treatments for Ichthyosis, as well as improving existing treatments. Show Less Read more